Today there’s essentially one model for drug production: make as much as possible. But J. Christopher Love, a professor of chemical engineering at the Massachusetts Institute of Technology, has spent the last five years pursuing a different vision: a desktop drug manufacturing process that would be fast and nimble enough to help combat a small disease outbreak, treat an unusual cancer, or replace a rare enzyme.

He’s not there yet, but in a paper published this week in Nature Biotechnology, Love and his colleagues showed that they can produce thousands of doses of clinical-quality biologically based drugs in about three days.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy